Venture capital investment is limited for biopharma startups in Israel, with only a few specialized funds active in the market and tough competition for money between biopharma, medtech and digital health companies. However, the sector is maturing and more money is coming in from private investors for early-research and clinical-stage companies.
Spotlight On Israel: Accessing Private Cash For Novel Technologies
Israel's appetite for biopharma investment is growing, but competition for cash is still tough and local investors are not only looking at regional startups to place their bets on.
More from Strategy
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
More from Business
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.